Between promise and responsibility: What makes a good health app

Quality criteria between evidence, data quality, and sustainable patient access

Health apps have long been part of strategic initiatives in pharmaceutical companies. Today, the question is no longer whether they are used, but which applications actually provide robust data and reach patients in the long term.

However, with the growing number of available solutions, choosing one is becoming more complex. The difference rarely lies in individual functions. What matters is how an application is structurally designed and how well it reflects everyday healthcare.

 

Platform logic instead of standalone solutions

Many health apps are focused on individual indications. They provide detailed data, but often remain isolated.

In everyday life, this is often not enough. Many patients live with several diseases at the same time (multimorbidity) and take different medications in parallel. Using several separate apps for this reality is neither practical nor sustainable. Applications that do not take this complexity into account generate fragmented data sets.

Cross-indication platforms go one step further here. They connect medication data, symptoms, and usage over longer periods of time, thereby reflecting everyday healthcare much more realistically.

For pharmaceutical companies and healthcare professionals (HCPs), this means that data can be better classified and compared, even across different treatment areas.

 

Data quality as a decisive factor

In the context of Real World Data, both the quality and quantity of data are decisive. A sufficient data basis is a prerequisite for statistical validity, at the same time, the way the data is collected determines how robust this data is.

Applications that guide users through everyday life in a structured way generally generate more complete and consistent datasets than those that rely on sporadic entries.

Linking data is particularly important. Medication information only becomes truly meaningful when it is considered in connection with symptoms, behavior, and changes over time.

Only this combination of continuous use and sufficient data volume creates datasets that are robust enough for Real World Evidence – as is also shown by digital treatment support as a source of structured patient insights.

 

Use determines informative value

A common problem with many health apps is the short duration of use. High download numbers say little if the application is no longer used after a short time.

For pharmaceutical companies, this has a direct consequence: The data remains incomplete, and analyses, for example on adherence, are only possible to a limited extent.

Applications that are used continuously in everyday life provide a different picture. They enable stable datasets and traceable courses over time.

Retention thus becomes a key metric, because it shows whether an app is actually being used — and whether the data obtained from it is robust. Because continuous data streams that open up new perspectives on treatment success only emerge through active patient engagement.

 

Relevant touchpoints in everyday life

The benefit of a health app emerges in the everyday lives of users.

Apps with only a few functions often lead only to occasional interactions. By contrast, platforms that reflect several aspects of treatment create regular points of contact, for example through medication management, symptom tracking, or information about the disease.

These recurring interactions lead to a better data basis and enable real-world insights into patient behavior — especially when applications also strengthen the digital health literacy of users.

For pharma and HCPs, this improves the basis for analyses and treatment decisions.

 

Medical quality and regulatory classification

The medical foundation remains the basis of every health app. Content must be evidence-based, up to date, and professionally accurate.

In addition, it is crucial that medical expertise is actually integrated into development, for example, through physicians or other qualified professionals. This not only increases the quality of the content, but also acceptance among patients and professional circles.

Certifications and regulatory classifications can also provide guidance, especially when applications are to be integrated into healthcare processes in the future.

 

Data protection and governance

Data protection is closely linked to trust and feasibility in the B2B context.

Clear structures are important: transparent data use, traceable data flows, and a clean separation between personal and aggregated data.

This is the prerequisite for applications to be used in the long term and integrated into existing processes.

 

Scalability as a strategic lever

Many digital projects do not fail because of the idea, but because of scaling.

Platform-based approaches offer clear advantages here. They can be used across several indications, reduce fragmented standalone solutions, and often also prove to be more stable in the market than isolated, indication-specific applications.

For pharmaceutical companies, this means less complexity and a more sustainable digital strategy.

 

Conclusion: Quality becomes apparent in practice

In the B2B context, health apps only create added value when they do more than offer individual functions.

What matters is whether they are used continuously, provide structured and reliable data, and can be integrated into existing systems.

Platform-based, cross-indication solutions offer the best prerequisites for this, especially when they bring together everyday healthcare reality, data quality, and scalability.

For pharmaceutical companies, the choice is therefore not a feature decision, but a question of the underlying system logic.